TY - JOUR
TI - Survival after secondary cytoreduction for recurrent ovarian cancer: Which are the prognostic factors?
AU - Biliatis, I.
AU - Haidopoulos, D.
AU - Rodolakis, A.
AU - Vlachos, G.
AU - Protopapas, A.
AU - Thomakos, N.
AU - Sergentanis, T.
AU - Akrivos, N.
AU - Antsaklis, A.
JO - International Journal of Surgical Oncology
PY - 2010
VL - 102
TODO - 6
SP - 671-675
PB - 
SN - 2090-1402, 2090-1410
TODO - 10.1002/jso.21686
TODO - paclitaxel;  platinum derivative, adult;  aged;  article;  cancer invasion;  cancer patient;  cancer recurrence;  cancer survival;  clear cell carcinoma;  clinical article;  colostomy;  cystectomy;  cytoreductive surgery;  disease free interval;  female;  histopathology;  human;  lymphadenectomy;  medical record review;  multiple cycle treatment;  ovary cancer;  overall survival;  peritoneal lymphadenectomy;  postoperative period;  priority journal;  prognosis;  retrospective study;  risk factor;  secondary cytoreduction;  splenectomy;  survival time;  treatment outcome, Antineoplastic Combined Chemotherapy Protocols;  Combined Modality Therapy;  Disease-Free Survival;  Female;  Humans;  Ovarian Neoplasms;  Prognosis;  Recurrence;  Reoperation;  Retrospective Studies;  Treatment Outcome
TODO - Objective Significant controversy exists concerning the factors affecting survival after secondary cytoreduction (SCR) in recurrent ovarian cancer. This study aims to identify factors independently associated with survival after SCR. Methods We retrospectively retrieved 39 patients with recurrent ovarian cancer. All patients had been initially treated with primary cytoreduction in our institution and received platinum- and paclitaxel-based chemotherapy postoperatively. Disease-free interval (DFI) had to be longer than 6 months. A variety of clinicopathological factors were recorded. Multivariable Cox regression was performed to examine the associations of parameters with survival. Results Median survival was equal to 24 months, the median DFI was 22 months, and complete SCR had been achieved in 19/39 patients (48.7%, 95% CI: 32.4-65.2%). Higher number of recurrence sites, clear-cell histological type, and more advanced FIGO stage were independently associated with shorter survival; longer DFI was associated with longer survival. Noticeably, complete SCR lost its significance at the multivariable model, although it was associated with longer survival at the univariable analysis. Conclusions Four factors seem capable of independently modifying survival after SCR: number of recurrence sites, DFI, FIGO stage, and clear cell histology. The two latter factors might reflect aggressive clinicopathological features of the tumor with long-term effect. © 2010 Wiley-Liss, Inc.
ER -